Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

in the ophthalmology, biopsy and general surgery areas, or medical device components manufactured by us and sold to other third-party medical device manufacturers who assemble those components into finished medical devices. Sales of our Base Medical Products are supported by a small group of direct sales personnel, as well as a network of independent sales representatives and medical product distributors. Sales of our Base Medical Products tend to exhibit greater volatility or slower relative growth, particularly our sales of components to third party medical device manufacturers, which may be impacted by customer concentration and the business issues that certain of our large customers may face, as well as to a more limited extent by economic and credit market conditions. Sales of our Base Medical Products declined by approximately 13% in the second quarter of 2009 as compared to the second quarter of 2008, and increased by approximately 2% as compared to the first quarter of 2009. Excluding the impact of foreign currency changes, revenue would have declined by 10% as compared to the second quarter of 2008. Foreign currency fluctuations did not have an impact on the change from the first quarter of 2009.

The decline in our Base Medical Products sales as compared to the second quarter of 2008 is due primarily to lower sales of medical device components to other third party medical device manufacturers, generally relating to certain customers that have postponed or cancelled orders, or implemented inventory reduction programs in response to changing economic and credit market conditions, and more particularly relating to cancelled orders for surgical needles by one of our largest customers. Manufacturing of surgical needles, as of November 2008, was fully transferred to our facility in Aguadilla, Puerto Rico from our facility in Syracuse, New York. We believe that the closure of our Syracuse production facility in November and the finalization of our move of
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015  ValGenesis Inc., the market leader ... that it has completed its Service Organization Controls 2 ... (AICPA, Professional Standards) for the period of January 1 ... ... The SOC 2 examination is ...
(Date:4/1/2015)... , Mar. 30, 2015 Research and Markets ... addition of the "Blood Screening Market by ... Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product ... - Forecasts to 2019 " report to ... is expected to reach $2.55 billion by 2019 ...
(Date:4/1/2015)... NEW YORK , April 1, 2015 ... biopharmaceutical company advancing protein biologic therapies and oncology ... the Company,s 2014 achievements and a strategic update ... progress the Company has made in the areas ... its MuGard programs, the FDA clearance of the ...
(Date:4/1/2015)... The concept of “spot reducing” areas is a huge ... Fasciology, Ashley Black, says that even the idea of being ... to wait for the whole fat system to reduce is ... cooling procedures, the only well known way to spot ... a highly invasive procedure.” It is common knowledge that weight ...
Breaking Biology Technology:ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3
... The medical imaging company SyntheticMR AB, ... order for their magnetic resonance imaging software from Umeå ... be used in clinical practice to monitor the treatment ... SyMRI Diagnostics, includes tools to automatically estimate a measure ...
... Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today announced James Levine, President and ... Mr. Levine will present at the upcoming ... September 12, 2011.  The presentation is expected to begin ...
... Switzerland, September 1, 2011 Study Assessing ... in mid 2012 Kuros Biosurgery AG, a ... and bioactive-biomaterial combination products for trauma, wound and spinal ... a Phase IIb clinical trial designed to investigate KUR-211 ...
Cached Biology Technology:Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3Verenium to Present at Upcoming Conferences 2Verenium to Present at Upcoming Conferences 3Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers 2Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers 3
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... In 2005, the overall cost of patients' time spent on cancer ... to a new study in the January 3 issue of the ... for the 11 cancers studied and for different phases of cancer ... the direct medical costs of cancer care, but few have attempted ...
... the January issue of the journal Cell Metabolism, published by ... the formation of a poorly understood type of muscle. Moreover, ... IIX fibers were able to run farther and at higher ... ultimately lead to novel drugs designed to change the composition ...
... insect cells ?not in eggs, where flu vaccines currently available ... effective as conventional vaccines in protecting people against the flu, ... the Journal of the American Medical Association. , Removing eggs ... health officials seeking to protect the population from seasonal flu ...
Cached Biology News:Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3'Marathon mice' elucidate little-known muscle type 2'Marathon mice' elucidate little-known muscle type 3Bypassing eggs, flu vaccine grown in insect cells shows promise 2Bypassing eggs, flu vaccine grown in insect cells shows promise 3
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
Biology Products: